NCT00311376 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder | Biotech Hunter

Enrollment

416

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Overactive Bladder

Interventions

BIOLOGICAL

botulinum toxin Type A (200U)

botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval

BIOLOGICAL

botulinum toxin Type A (300U)

botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at \> 12 weeks interval

OTHER

Normal Saline (Placebo); botulinum toxin Type A (200U)

Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval

OTHER

Normal Saline (Placebo); botulinum toxin Type A (300U)

Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at \> 12 weeks interval

Trial Locations (14)

Royal Oak

Randwick

Innsbruck

Ghent

Sherbrooke

Ostrava

Garches

Halle

Christchurch

Wroclaw

Moscow

Martin

Lviv

London